Tight control for Crohn's disease with adalimumab-based treatment is cost-effective: An economic assessment of the CALM trial

Remo Panaccione, Jean Frederic Colombel, Simon P.L. Travis, Peter Bossuyt, Filip Baert, Tomáš Vanásek, Ahmet Danalioglu, Gottfried Novacek, Alessandro Armuzzi, Walter Reinisch, Scott Johnson, Marric Buessing, Ezequiel Neimark, Joel Petersson, Wan Ju Lee, Geert R. D'Haens

Research output: Contribution to journalArticlepeer-review

15 Scopus citations

Fingerprint

Dive into the research topics of 'Tight control for Crohn's disease with adalimumab-based treatment is cost-effective: An economic assessment of the CALM trial'. Together they form a unique fingerprint.

Medicine & Life Sciences